Instil Bio, Inc.

DALLAS, TX · Founded 2018 · CIK 0001789769 · Biotech · Public

CAR-T cell therapies for hematologic malignancies and solid tumors

instilbio.com →
Grants
—
No SBIR or STTR on record
Sector median: 1
Raised
$371M
4 Form D · Feb 2021
68 months since last filing
Contracts
—
No federal contracts on record
Patents
33
1 granted · 32 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Private capital raisedForm D · SEC$15,000,000
Private capital raised· 1 of 2 same dayForm D · SEC$170,199,973
Private capital raised· 2 of 2 same dayForm D · SEC$515,917
Private capital raisedForm D · SEC$185,449,881
Form D · SEC

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2778Genetic Networks, LLC——
2779FLUIDFORM INC——
2780Tentarix——
2781Instil Bio, Inc.—$371M
2782Legend Biotech Corp—$350M
2783Sensei Biotherapeutics, Inc.—$349M
2784X4 Pharmaceuticals—$313M

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Founders & Team

From Form D filings · 11 related persons
  • Gwen BinderDirector
  • Bronson CrouchDirector · Executive Officer
  • Neil GibsonDirector
  • Robert HawkinsDirector
  • Sandeep LaumasExecutive Officer
  • George MatchamDirector
  • Kent McGaughyDirector
  • Mariam MorrisExecutive Officer
  • Jack NielsenDirector
  • Margo RobertsDirector
  • Nimish ShahDirector

Patents

USPTO · 1 granted of 33
  • Processing Of Tumor Infiltrating Lymphocytesapplication
  • Methods Of Isolating Of Tumor Infiltrating Lymphocytes And Use Thereofapplication
  • Processing Of Tumor Infiltrating Lymphocytesapplication
  • Receptors Providing Targeted Costimulation For Adoptive Cell Therapygranted
  • Receptors Providing Targeted Costimulation For Adoptive Cell Therapyapplication
  • Receptors Providing Targeted Costimulation For Adoptive Cell Therapyapplication
  • Tumor Infiltrating Lymphocytes And ANTI-PD-1 Antibody Combination Therapy For The Treatment Of Cancerapplication
  • Tumor-infiltrating Lymphocyte (til) Compositions And Uses Thereofapplication
  • Methods For Identifying Tcr Repertoire And Compositions And Uses Thereofapplication
  • Receptors Providing Targeted Costimulation For Adoptive Cell Therapyapplication
  • Processing Of Tumor Infiltrating Lymphocytesapplication
  • Tumor Infiltrating Lymphocytes And ANTI-PD-1 Antibody Combination Therapy For The Treatment Of Cancerapplication

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.